Study Description: The purpose of this study is to test a possible new treatment for schizophrenia and/or schizoaffective disorder. Siltuximab will be administered, in addition to your current psychiatric medications, to determine its safety, tolerability, and effectiveness in patients with schizophrenia or schizoaffective disorder. Several studies suggest that inflammation ? the complex response of the body?s blood vessels to injury - may contribute to symptoms in schizophrenia and/or schizoaffective disorder, including impaired cognition (thinking). Inflammation does not mean infection. Siltuximab, a drug that was approved by the U.S. Food and Drug Administration in 2010 for the treatment of adults with Castleman's disease, helps reduce inflammation. Siltuximab is administered as an intravenous (IV) infusion (the medication is given through a small tube placed in a vein in your arm or hand) once every 3 weeks.
Principal Investigator: Brian Miller
Eligibility Criteria: Inclusion: - Age 18-55 - Diagnosis of schizophrenia or schizoaffective disorder - Taking antipsychotic medication, and no changes in psychiatric medications for 4 weeks - Not hospitalized in the past 3 months
Compensation: Yes, subjects will be compensated.
Compensation Explanation: They will receive a check in the amount of $50 for completing the first (Screening) visit, $100 for completing the second visit (Baseline visit and first Siltuximab infusion), $100 for completing the third visit (3 week follow up and second Siltuximab infusion), $100 for completing the fourth visit (6 week follow-up and third Siltuximab infusion), and $100 for completing the fifth visit (9 week follow-up) in this study.
If you don't see specific studies that interest you, please submit your contact information for future studies.